Paid Clinical Trials South Carolina
Discover 1,304 paid clinical trials in South Carolina. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic MigraineA Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT04616326
Conditions
Chronic Migraine
Eligibility Criteria
Sex: All
Age: 12 - 17
Healthy Volunteers: Not accepted
Interventions
Galcanezumab
Placebo
COAST Therapy in Advanced Solid Tumors and Prostate CancerCOAST Therapy in Advanced Solid Tumors and Prostate Cancer
Sponsor:
Medical University of South Carolina
Location:
Code:
NCT05036226
Conditions
Prostate Cancer Recurrent
Solid Tumor, Adult
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Hydroxychloroquine, Metformin, Sirolimus
Hydroxychloroquine, Metformin, Sirolimus, Dasatanib
Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir
Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib
The Arteriovenous Vascular (AV) ACCESS TrialThe Arteriovenous Vascular (AV) ACCESS Trial
Sponsor:
Wake Forest University Health Sciences
Location:
Code:
NCT04646226
Conditions
End-Stage Kidney Disease
Hemodialysis Complication
Eligibility Criteria
Sex: All
Age: 60+
Healthy Volunteers: Not accepted
Interventions
AV graft
surgical intervention for creation of a fistula
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT05026866
Conditions
Alzheimer Disease
Eligibility Criteria
Sex: All
Age: 65 - 70+
Healthy Volunteers: Not accepted
Interventions
Donanemab
Placebo
Primary Subtalar Arthrodesis for Calcaneal FracturesPrimary Subtalar Arthrodesis for Calcaneal Fractures
Sponsor:
Wake Forest University Health Sciences
Location:
Code:
NCT06249126
Conditions
Calcaneus Fracture
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Primary Fusion (Open Reduction Internal Fixation (ORIF) + Primary Subtalar Arthrodesis (PSTA)
Open Reduction Internal Fixation (ORIF) only
An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLSAn Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
Sponsor:
XenoPort, Inc.
Location:
Code:
NCT02560766
Conditions
RLS
Eligibility Criteria
Sex: All
Age: 13 - 17
Healthy Volunteers: Not accepted
Interventions
HORIZANT 300 mg
HORIZANT 600 mg
Placebo
Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy AloneEffectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone
Sponsor:
Introgen Therapeutics
Location:
Code:
NCT00041626
Conditions
Carcinoma, Squamous Cell
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
INGN 201
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSELutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
Sponsor:
ITM Solucin GmbH
Location:
Code:
NCT04919226
Conditions
Neuroendocrine Tumors
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT
CAPTEM (Capecitabine and Temozolomide)
Amino-Acid Solution
Everolimus
FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade GliomaA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03871257
Conditions
Low Grade Glioma
Neurofibromatosis Type 1
Visual Pathway Glioma
Eligibility Criteria
Sex: All
Age: 2 - 21
Healthy Volunteers: Not accepted
Interventions
Carboplatin
Magnetic Resonance Imaging
Quality-of-Life Assessment
Questionnaire Administration
Selumetinib Sulfate